Current standard practices to mitigate recurrent cardiovascular events routinely involve lifestyle modifications, such as dietary adjustments, physical activity, smoking cessation, and weight management. These lifestyle interventions, when utilized in conjunction with medical therapies—which may include platelet inhibitors, antihypertensive agents, and statins aimed at lowering low-density lipoprotein (LDL) cholesterol levels—form the bedrock of prevention strategies. However, it is increasingly evident that these measures do not entirely encapsulate the complex pathophysiological landscape that underlies atherosclerosis and its complications.

While lifestyle changes and common therapeutic approaches are pivotal, they may only partially address the multifaceted nature of cardiovascular pathology. Recent studies indicate that other biological and inflammatory mechanisms could contribute significantly to the residual risk observed in CAD patients. For instance, factors like endothelial dysfunction, oxidative stress, and chronic inflammation appear to play crucial roles in disease progression and plaque instability, yet they remain less targeted in traditional treatment paradigms.

The evolving understanding of these mechanisms invites a broader perspective on how we may better stratify and manage risks associated with CAD. Important contributors to recurrent cardiovascular events include various biomarkers that reflect underlying biological processes. Elevated levels of high-sensitivity C-reactive protein (hs-CRP), for instance, are indicative of inflammation and have been associated with increased cardiovascular risk, revealing pathways that conventional treatment modalities might overlook. Other emerging biomarkers linked to cardiovascular risk include lipoprotein(a) and biomarkers of myocardial necrosis, which could provide essential insights into an individual’s risk profile.

The introduction of novel therapies offers a promising ray of hope for tackling the residual risk that conventional approaches may leave unaddressed. Recent clinical trials are investigating the efficacy of drugs that target previously neglected pathways associated with atherosclerosis and inflammation. For instance, therapies that inhibit interleukin-1β, a pro-inflammatory cytokine, have shown potential in reducing cardiovascular events in high-risk individuals. The engagement of these therapies in standard care could redefine the paradigm of treating coronary artery disease, making for more comprehensive risk management strategies.

In parallel, integrating digital health technologies into clinical practice offers a new frontier for reducing cardiovascular risk. Digital tools can enhance patient engagement through real-time monitoring, providing feedback on lifestyle adherence, and fostering greater accountability. Telemedicine and mobile health applications become indispensable allies in promoting preventive measures and achieving optimum health outcomes. These innovations may also facilitate personalized medicine approaches, allowing clinicians to tailor interventions based on individual risk factors and responses.

Another perspective worth considering pertains to the broader societal and behavioral determinants of health that may be contributing to residual cardiovascular risk. Socioeconomic status, access to healthcare, and social support networks can all shape health behaviors and influence treatment adherence. Addressing these social determinants is a critical element in any comprehensive strategy designed to reduce the burden of cardiovascular disease. Ensuring equitable access to care and resources remains a pressing challenge, necessitating systemic change at multiple levels of society.

Despite these complexities, the interplay between established and novel therapies marks a new chapter in managing residual cardiovascular risk. The need for a coordinated, multidisciplinary approach to patient care is paramount, ensuring that cardiovascular specialists, primary care providers, and allied health professionals collaborate seamlessly to optimize treatment regimens. Moreover, research serves as the backbone of uncovering better therapeutic strategies. The more we explore the intricate webs of biological mechanisms at play, the better we can address the unrelenting challenge posed by coronary artery disease.

As clinical evidence mounts, there is no denying that the impact of residual cardiovascular risk extends beyond the clinical setting. It affects patient quality of life, economic costs of healthcare, and public health outcomes. With this in mind, it becomes essential to prioritize research initiatives that delve into the nuances of cardiovascular pathology and resilience. The endeavor to close the gap left by traditional treatment modalities must encompass a holistic view of health—one that recognizes the unity of biological, behavioral, and environmental dimensions of cardiovascular risk.

The pursuit of knowledge, innovation, and comprehensive strategies remains a shared responsibility among healthcare professionals, researchers, and patients alike. The evolution of cardiovascular therapies represents a significant stride forward, but it is equally vital to acknowledge and address the gaps that persist. As we strive to bring the light of understanding to the ever-complex realm of cardiovascular disease, we move closer to realizing the vision of reduced residual risk and improved outcomes for those affected by coronary artery disease. This challenging yet crucial journey is not simply about treating existing conditions but rather about fostering a future where cardiovascular health is attainable for all.

As we stand at this important juncture in cardiovascular research and therapy, renewed collaboration, vigorous inquiry, and innovative thinking will be the driving forces behind transformative change. In the relentless battle against atherosclerosis and its consequential risks, a multi-faceted approach that encompasses prevention, personalized care, and a deeper appreciation of underlying mechanisms will be key to pushing boundaries and redefining standards of care in coronary artery disease management.

Through these collective efforts, we hold the potential to significantly mitigate residual cardiovascular risk and usher in a new era of hope for individuals grappling with the ongoing challenges posed by coronary artery disease.

Subject of Research: Residual cardiovascular risk in coronary artery disease.

Article Title: Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.

Article References:

Galli, M., Abbate, A., Bonaca, M.P. et al. Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.
Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01249-z

Image Credits: AI Generated

DOI: 10.1038/s41569-026-01249-z

Keywords: Atherosclerosis, coronary artery disease, residual cardiovascular risk, secondary prevention, biomarkers, inflammation, novel therapies, lifestyle modification, digital health technologies, socioeconomic factors.

The PREVENT™ risk calculator, launched in 2023 by the American Heart Association, provides an integrative risk assessment for cardiovascular events by estimating the likelihood of heart attack, stroke, and heart failure over the subsequent 10 and 30 years. Unique among risk prediction tools, PREVENT incorporates an array of physiological, metabolic, and social determinants of health, including age, blood pressure, cholesterol, body mass index, Type 2 diabetes status, smoking habits, kidney function, and socioeconomic factors. This multifaceted approach enables a nuanced and comprehensive evaluation of cardiovascular risk.

Central to this study was an analysis of nearly 7,000 adults who underwent coronary computed tomography angiography (CCTA) at NYU Langone Health between 2010 and 2024. CCTA is a sophisticated imaging modality that non-invasively visualizes atherosclerotic plaque within the coronary arteries. Patients receive a coronary artery calcium (CAC) score from this imaging, quantifying calcium deposits as an established marker of coronary atherosclerosis and cardiovascular risk.

The investigators set out to explore the concordance between PREVENT risk scores and CAC scores and to determine whether combining these measures would enhance the accuracy of predicting heart attack risk. The study population—adults aged 30 to 79 with no prior heart disease history—provided a well-characterized cohort to investigate these relationships in a real-world clinical setting.

Results revealed a direct correlation between PREVENT scores and CAC scores. Individuals with low to mildly elevated PREVENT scores corresponded with minimal coronary calcium deposits, reflected by CAC scores of 1 or less, indicating low cardiovascular risk. Conversely, those with moderate to high PREVENT risk levels exhibited significantly elevated CAC scores exceeding 100, marking a higher burden of subclinical atherosclerosis and increased risk of adverse cardiac events.

Critically, when the researchers integrated PREVENT risk calculations with CAC data, they achieved superior predictive accuracy for future heart attacks, outperforming either measure alone. This combined approach successfully identified patients who experienced heart attacks during the follow-up period more precisely, underscoring the complementary nature of physiological risk profiling and direct imaging evidence of coronary artery disease.

The significance of these findings lies in their potential to refine clinical risk stratification and optimize preventive interventions. Dr. Morgan Grams, the study’s corresponding author, emphasized that improved cardiovascular risk prediction facilitates tailored therapeutic decision-making, such as initiating or intensifying cholesterol-lowering regimens. Early identification of patients harboring subclinical arterial plaque enables more timely and aggressive risk-reduction strategies before symptomatic disease manifests.

Incorporating social determinants of health into the PREVENT algorithm represents a meaningful advancement, acknowledging the complex interplay of environmental and behavioral factors in cardiovascular disease development. By embedding these variables alongside traditional clinical parameters, PREVENT may better capture the heterogeneity of patient risk profiles encountered in diverse clinical populations.

The utilization of CAC scoring via CCTA complements this approach by offering a direct anatomical assessment of coronary atherosclerosis burden. While blood-based risk factors predict susceptibility to plaque formation, CAC scoring quantifies the actual disease extent, bridging functional risk estimates and structural pathology. This synthesis provides clinicians with a powerful tool to identify and manage patients at greatest imminent risk.

Nevertheless, the study also acknowledges certain limitations inherent in its design. The single-center, retrospective cohort predominantly comprised White participants, which may restrict extrapolation of the findings to broader, more ethnically diverse populations. Additionally, the average follow-up duration was relatively short, at 1.2 years, constraining long-term risk assessment. The study also did not assess non-calcified plaques, which can contribute to cardiovascular events but are not captured by CAC scoring.

Furthermore, the cohort consisted exclusively of patients referred for CCTA and CAC scoring by healthcare providers, implying potential preselection bias with a higher baseline cardiovascular risk compared to the general population. Reliance on electronic health records for data extraction, though comprehensive, also introduces the possibility of coding inaccuracies or underreporting of clinical events.

Despite these caveats, the study represents an important step forward in cardiovascular risk prediction science. By validating the real-world applicability of the PREVENT risk calculator in conjunction with CAC imaging, the research offers a blueprint for integrating multifactorial risk assessment into routine clinical workflows. This may ultimately contribute to reducing the incidence of heart attacks and improving population cardiovascular health.

As cardiovascular disease remains the leading cause of mortality worldwide, innovations in risk stratification tools are crucial to guide preventive therapies effectively. The combination of quantitative imaging and personalized risk modeling heralds a future where interventions can be more precisely tailored, minimizing both under- and overtreatment.

Going forward, multicenter studies including diverse demographic groups and longer follow-up periods will be essential to confirm and expand upon these findings. Additionally, incorporating assessments of non-calcified plaque and other emerging biomarkers may further enhance the accuracy and utility of predictive models like PREVENT.

In summary, this study compellingly demonstrates that the PREVENT™ risk calculator is not only reflective of underlying coronary artery calcium burden but also has enhanced predictive capacity when combined with CAC scores for future heart attack risk. These insights are poised to influence clinical guidelines and augment decision-making in cardiovascular disease prevention.

Subject of Research: Cardiovascular Risk Prediction and Coronary Artery Calcium Scoring

Article Title: Real-World Evidence Linking the Predicting Risk of Cardiovascular Disease Events Risk Score and Coronary Artery Calcium

News Publication Date: May 21, 2025

Web References:

• PREVENT Risk Calculator: https://professional.heart.org/en/guidelines-and-statements/prevent-calculator
• Journal of the American Heart Association: https://www.ahajournals.org/journal/jaha
• Coronary Artery Calcium Score: https://www.heart.org/en/health-topics/heart-attack/diagnosing-a-heart-attack/cac-test

References:

• DOI: 10.1161/JAHA.124.038991 (https://dx.doi.org/10.1161/JAHA.124.038991)

Keywords: cardiovascular risk, PREVENT risk calculator, coronary artery calcium, CAC score, heart attack prediction, cardiovascular disease, coronary computed tomography angiography, CCTA, atherosclerosis, risk stratification, primary prevention, real-world evidence